{
  "drug_name": "Cefipime",
  "url": "https://wikem.org/wiki/Cefipime",
  "scraped_at": "2026-01-10T03:06:18.686552",
  "sections": {
    "General": {
      "text": "Type: Fourth generation\ncephalosporin\nDosage Forms: infusion solution, powder for injection\nDosage Strengths: infusion solution: 1g/50mL, 2g/100mL; powder for injection: 1g, 2g\nRoutes of Administration: IV, IM\nCommon Trade Names: Maxipime",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "cephalosporin",
          "url": "https://wikem.org/wiki/Cephalosporins"
        }
      ]
    },
    "Adult_Dosing": {
      "text": "1-2 g IV q12h",
      "subsections": {
        "febrile_neutropenia": {
          "text": "2g IV q8h",
          "tables": []
        },
        "UTI,_mild-mod": {
          "text": "0.5g - 1g q12h x 7-10days",
          "tables": []
        },
        "UTI,_severe": {
          "text": "2g IV q12h x 10days",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Pediatric_Dosing": {
      "text": "",
      "subsections": {
        "infection,_bacterial": {
          "text": ">2 months\n50mg/kg IV/IM q12hr, max 2g/dose",
          "tables": []
        },
        "febrile_neutropenia_2": {
          "text": ">2 months\n50mg/kg IV/IM q8h; max 2g/dose",
          "tables": []
        },
        "resp._infection,_cystic_fibrosis_patients": {
          "text": "> 2 months\n50mg/kg IV/IM q8h; max 2g/dose",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Special_Populations": {
      "text": "Pregnancy: Category B (no evidence of risk in humans)\nLactation: very small amount excreted, adverse effects unlikely, infant should be monitored closely\nRenal Dosing\nAdult\nfebrile neutropenia\nGFR 30-60: 2g q12h\nGFR 11-29: 2g q24h\nGFR < 11: 2g x1, then 1g q24h\nHD: 1g q24, give after dialysis\nPD: 2g q24h\nall other infections\nGFR 30-60: q24h dosing\nGFR 11-29: give usual dose x1, then 0.5-1g q24\nGFR < 11: give usual dose x1, then 250-500mg q24h\nHD: 1g x1, then 500mg q24h, give after dialysis\nPD: usual dose q48h\nPediatric\nfebrile neutropenia, cystic fibrosis\nGFR 30-60: 50mg/kg q12h\nGFR 11-29: 50mg/kg q24h\nGFR < 11: 50mg/kg x1, then 25mg/kg q24\nHD: 25mg/kg q24, give after dialysis\nPD: 50mg/kg q48\nall other infections\nGFR 30-60: 50mg/kg q24\nGFR 11-29: 50mg/kg x1, then 25-50mg/kg q24\nGFR < 11: 50mg/kg x1, then 12.5-25mg/kg q24h\nHD: 50mg/kg x1, then 25mg/kg q24h, give after dialysis\nPD: 50mg/kg q48h\nHepatic Dosing\nAdult: no adjustment\nPediatric: no adjustment",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Contraindications": {
      "text": "Allergy to class/drug",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Adverse_Reactions": {
      "text": "",
      "subsections": {
        "Serious": {
          "text": "anaphylaxis\nencephalopathy\nseizures\nnon-convulsive status epilepticus\nleukopenia\nthrombocytopenia\nagranulocytosis\nanemia, hemolytic\naplastic anemia\nhemorrhage\nStevens Johnson Syndrome\ntoxic epidermal necrolysis\nerythema multiforme\nC.difficile associated diarrhea",
          "tables": []
        },
        "Common": {
          "text": "rash\ninfection site reaction\ndiarrhea\nhypophosphatemia\nALT, AST elevation\nnausea",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Pharmacology": {
      "text": "Half-life:\n2h, 13.5h (HD), 19h(CAPD)\nMetabolism:\nminimal, site unknown\nExcretion:\nurine primarily (85% unchanged)\nMechanism of Action:\nbacteriacidal, inhibits cell wall mucopeptide synthesis",
      "subsections": {},
      "tables": [],
      "links": []
    }
  }
}